Pen­ny stock biotech miss­es on its sole clin­i­cal tri­al; Cal­adrius teams up with Roche for pan­cre­at­ic can­cer col­lab­o­ra­tion

Vyne Ther­a­peu­tics had put all its clin­i­cal fo­cus on one drug: FMX114 for mild-to-mod­er­ate atopic der­mati­tis. How­ev­er, that tri­al, Vyne’s on­ly on­go­ing clin­i­cal tri­al, has …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER